866-997-4948(US-Canada Toll Free)

Graft Versus Host Disease (GVHD) Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 157 Pages


Global Markets Directs, \'Graft Versus Host Disease (GVHD) Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD). 

Graft Versus Host Disease (GVHD) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Graft Versus Host Disease (GVHD).
  • A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Graft Versus Host Disease (GVHD) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Graft Versus Host Disease (GVHD) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Graft Versus Host Disease (GVHD) 8
Graft Versus Host Disease (GVHD) Therapeutics under Development by Companies 10
Graft Versus Host Disease (GVHD) Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Graft Versus Host Disease (GVHD) Therapeutics Products under Development by Companies 20
Graft Versus Host Disease (GVHD) Therapeutics Products under Investigation by Universities/Institutes 22
Companies Involved in Graft Versus Host Disease (GVHD) Therapeutics Development 24
Osiris Therapeutics, Inc. 24
Athersys, Inc. 25
Seattle Genetics, Inc. 26
AbGenomics International, Inc. 27
Novartis AG 28
IMMUNOMEDICS, INC 29
Jazz Pharmaceuticals, Inc. 30
Soligenix, Inc. 31
NeoStem, Inc. 32
Palau Pharma S.A 33
Pharmagenesis, Inc. 34
Alder Biopharmaceuticals Inc. 35
Kiadis Pharma B.V. 36
ADIENNE Pharma & Biotech 37
Dr. Falk Pharma GmbH 38
Lycera Corp. 39
Sigmoid Pharma. 40
Graft Versus Host Disease (GVHD) Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 48
brentuximab vedotin - Drug Profile 48
MultiStem - Drug Profile 53
remestemcel-L - Drug Profile 55
milatuzumab - Drug Profile 57
ATIR - Drug Profile 59
Rhitol - Drug Profile 60
orBec - Drug Profile 61
orBec - Drug Profile 63
clazakizumab - Drug Profile 65
inolimomab - Drug Profile 67
bortezomib + [tacrolimus] + [methotrexate] - Drug Profile 68
aldesleukin - Drug Profile 69
dexamethasone acetate + tacrolimus - Drug Profile 70
budesonide - Drug Profile 71
Therapeutic allogeneic lymphocytes program - Drug Profile 73
etanercept - Drug Profile 74
Aptamer-Targeted Costimulatory Ligand Aptamer - Drug Profile 76
aldesleukin - Drug Profile 77
denileukin diftitox + [Corticosteroids] - Drug Profile 79
ApoCell - Drug Profile 80
abatacept + [cyclosporine] + [methotrexate] - Drug Profile 81
Alpha-1 Antitrypsin - Drug Profile 82
fludarabine phosphate + thiotepa + [tacrolimus] + Allogeneic Blood Stem Cell Transplantation - Drug Profile 84
rituximab + [Anti-Thymocyte Globulin] + [busulfan] + [cyclophosphamide] + [fludarabine phosphate] + [mycophenolate mofetil] + [tacrolimus] + Stem Cell Transplantation + Radiation Therapy - Drug Profile 85
Human Minor H Antigen Peptide Vaccine - Drug Profile 87
Allodepleted T Cells - Drug Profile 88
bortezomib - Drug Profile 89
atorvastatin calcium - Drug Profile 90
sirolimus + mycophenolate mofetil - Drug Profile 91
pentostatin - Drug Profile 92
Allogeneic Bone Marrow Mesenchymal Stem Cells - Drug Profile 93
Tetrandrine - Drug Profile 94
Homeo-GH - Drug Profile 95
Bioenergetics Program - Drug Profile 96
Bz-423 - Drug Profile 97
Cyclophosphamide + Sirolimus - Drug Profile 98
Athelos T Cell Therapeutic - Drug Profile 99
MesoStem - Drug Profile 100
Brentuximab Vedotin - Drug Profile 101
ImmuStem - Drug Profile 102
beclomethasone dipropionate - Drug Profile 103
Drug For Graft Versus Host Disease - Drug Profile 104
Jak3/Syk Dual Inhibitor - Drug Profile 105
Bone Marrow Stromal Cells - Drug Profile 106
clobetasol propionate + [dexamethasone acefurate] - Drug Profile 107
Alpha-1-Antitrypsin - Drug Profile 108
PG-27 - Drug Profile 109
Mesenchymal Stem Cells - Drug Profile 110
T-Guard - Drug Profile 111
Graft Versus Host Disease (GVHD) Therapeutics Drug Profile Updates 112
Graft Versus Host Disease (GVHD) Therapeutics Discontinued Products 140
Graft Versus Host Disease (GVHD) Therapeutics - Dormant Products 141
Graft Versus Host Disease (GVHD) Product Development Milestones 144
Featured News & Press Releases 144

Appendix 152
Methodology 152
Coverage 152
Secondary Research 152
Primary Research 152
Expert Panel Validation 152
Contact Us 153
Disclaimer 153

List of Table


Number of Products Under Development for Graft Versus Host Disease (GVHD), H1 2013 12
Products under Development for Graft Versus Host Disease (GVHD) Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 19
Comparative Analysis by Late Stage Development, H1 2013 20
Comparative Analysis by Mid Clinical Stage Development, H1 2013 21
Comparative Analysis by Early Clinical Stage Development, H1 2013 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 23
Products under Development by Companies, H1 2013 24
Products under Development by Companies, H1 2013 (Contd..1) 25
Products under Investigation by Universities/Institutes, H1 2013 26
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 27
Osiris Therapeutics, Inc., H1 2013 28
Athersys, Inc., H1 2013 29
Seattle Genetics, Inc., H1 2013 30
AbGenomics International, Inc., H1 2013 31
Novartis AG, H1 2013 32
IMMUNOMEDICS, INC, H1 2013 33
Jazz Pharmaceuticals, Inc., H1 2013 34
Soligenix, Inc., H1 2013 35
NeoStem, Inc., H1 2013 36
Palau Pharma S.A, H1 2013 37
Pharmagenesis, Inc., H1 2013 38
Alder Biopharmaceuticals Inc., H1 2013 39
Kiadis Pharma B.V., H1 2013 40
ADIENNE Pharma & Biotech, H1 2013 41
Dr. Falk Pharma GmbH, H1 2013 42
Lycera Corp., H1 2013 43
Sigmoid Pharma., H1 2013 44
Assessment by Monotherapy Products, H1 2013 45
Assessment by Combination Products, H1 2013 46
Assessment by Stage and Route of Administration, H1 2013 48
Assessment by Stage and Molecule Type, H1 2013 51
Graft Versus Host Disease (GVHD) Therapeutics Drug Profile Updates 116
Graft Versus Host Disease (GVHD) Therapeutics Discontinued Products 144
Graft Versus Host Disease (GVHD) Therapeutics Dormant Products 145
Graft Versus Host Disease (GVHD) Therapeutics Dormant Products (Contd..1) 146
Graft Versus Host Disease (GVHD) Therapeutics Dormant Products (Contd..2) 147

List of Chart


Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2013 12
Products under Development for Graft Versus Host Disease (GVHD) Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 20
Mid Clinical Stage Products, H1 2013 21
Early Clinical Stage Products, H1 2013 22
Discovery and Pre-Clinical Stage Products, H1 2013 23
Assessment by Monotherapy Products, H1 2013 45
Assessment by Combination Products, H1 2013 46
Assessment by Route of Administration, H1 2013 47
Assessment by Stage and Route of Administration, H1 2013 48
Assessment by Molecule Type, H1 2013 49
Assessment by Stage and Molecule Type, H1 2013 50

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *